Epic Tools for Epic Science

As Bio-Techne, we have united multiple brands to provide a unique and comprehensive product portfolio. Together, our brands provide world class products and services for life-science research and clinical applications.

Investor Presentation

Latest Presentation

June 29, 2018

Bio-Techne to Acquire Exosome Diagnostics

View Presentation View All


Reportable Segments

  • Biotechnology R&D Systems®, PrimeGene®, Novus Biologicals®, Tocris®
  • Diagnostics R&D Systems®, Cliniqa®, Bionostics®, BiosPacific®
  • Protein Platforms ProteinSimple®, Simple Plex™, Milo™


Customer Segmentation

  • Pharma/Biotechnology
  • Academia
  • OEM
  • Distributors



  • Americas
  • EMEA
  • APAC

Latest Quarterly Results

FY 2018

Fiscal Year Ended Jun 30, 2018

Get Alerts

$180 million

Net Sales

$122 Million

Gross Margin

$41 Million

Net Earnings

Sign up for E-Mail Alerts

Sign up today

Latest Annual Highlights


Fiscal 2018 Net Sales


Fiscal 2018 Operating Income

View 10-K Get Alerts

Stock Information

Bio-Techne Corporation

Nasdaq: TECH

 |  View Detailed Stock Info

Day Range
52 Week Range

Company Overview

Bio-Techne Corporation (NASDAQ: TECH) is a leading developer and manufacturer of high quality purified proteins - notably cytokines and growth factors, antibodies, immunoassays, as well as biologically active small molecule compounds and ACD’s in situ hybridization detection products - which are sold to biomedical researchers and clinical research laboratories; these operations constitute the core Biotechnology Division, headquartered in Minneapolis, Minnesota.

The Protein Platform Division manufactures innovative protein analysis tools under the ProteinSimple brand name that greatly automate western blotting and immunoassay practices. The Diagnostics Division manufactures FDA-regulated controls, calibrators, blood gas and clinical chemistry controls and other reagents for OEM customer and clinical customers. Bio-Techne products are integral components of scientific investigations into biological processes and the nature, etiology and progression of specific diseases. They aid in drug discovery efforts and provide the means for accurate clinical tests and diagnoses.

With thousands of products in its portfolio, Bio-Techne generated approximately $643 million in net sales in fiscal 2018 and has over 2,100 employees worldwide.

Fast Facts

Net sales (July 2016 to June 2017)

$563 million

Employees Worldwide




Journal citations


Incorporated in Minneapolis, Minnesota



Our people are our backbone. Touting years of experience in a variety of fields, our leadership team is a source of our success.

IR Contact Information

Company Information

Corporate Secretary
614 McKinley Place NE
Minneapolis, MN 55413

Investor Relations

David Clair
T: 646-277-1266

Transfer Agent

American Stock Transfer
6201 15th Avenue
Brooklyn, NY 11219
T: 800-937-5449